Spinal cord injury (SCI) disrupts neural circuitry through acute mechanical trauma followed by secondary degeneration—inflammation, ischaemia, apoptosis—that extends the initial lesion zone over hours to days. Neurogenic stem cells and neural progenitor cells derived from umbilical cord or fetal sources can differentiate into oligodendrocytes (restoring myelin) and astrocytes (stabilising the lesion core), whilst also secreting neurotrophic factors (BDNF, NGF, NT-3) that promote axonal plasticity and regeneration. Placental mesenchymal stem cells provide complementary neuroprotection and angiogenesis. Sixty-nine registered trials and eight actively recruiting centres explore cell transplantation, often combined with rehabilitation, in both acute (<2 weeks) and chronic (>6 months) SCI populations.
Clinical trial data spans phase I safety (no serious adverse events in >300 recipients) through phase II efficacy assessment. Representative studies in chronic SCI (>1 year post-injury) report motor score improvements (ASIA scale) of 2–6 points in 35–50% of treated cohorts over 12 months, with some sensory recovery (pin-prick, light-touch perception restoration) in 20–30%. Neuroimaging (DTI, fMRI) shows increased white-matter fractional anisotropy and expanded motor-cortex activation maps in responders. Acute-phase trials show more variable outcomes; lesion cavity volume reduction has been documented but functional translation remains uncertain.
SCI stem-cell protocols in Sofia and international centres range €8,000–12,000 for comprehensive treatment, incorporating 1–3 intraspinal cell injections (requiring neurosurgical expertise and operative suite time), baseline and serial neuroimaging (MRI, CT), neuroelectrophysiological testing (EMG, evoked potentials), and intensive post-operative rehabilitation (3–6 months). Neurosurgical consultation, anaesthesia, and inpatient recovery add to facility costs. Travel and accommodation for international patients constitute substantial additional burden.
Cell therapy for Spinal Cord Injury is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Spinal Cord Injury programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Spinal Cord Injury overview · Spinal Cord Injury cost →
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite